Seaport Therapeutics

Seaport Therapeutics (Ticker: SPTX US) develops medicines for depression, anxiety, and other neuropsychiatric disorders, including oral therapies made with its Glyph platform. It is a clinical-stage therapeutics company. Its approach focuses on clinically validated mechanisms that have been difficult to use because the body breaks down medicines before they reach circulation or absorbs too little of them.

The scheduled listing date on Nasdaq was April 30, 2026. The proposed offering comprises 11,800,000 shares at an indicative price range of $16.00–18.00 per share. At the indicative range midpoint, the base offering would represent $200.60 million in gross proceeds, excluding any unexercised over-allotment.

Goldman Sachs, J.P. Morgan, Leerink, Citi, and Stifel are lead bookrunners; J.P. Morgan is the stabilization agent.